PPARα/δ dual agonist H11 alleviates diabetic kidney injury by improving the metabolic disorders of tubular epithelial cells
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Qingqing Ke und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Kidney Disease, The Second Affiliated Hospital of Nanjing Medical University, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Metabolic Diseases, PPAR delta. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China, China Pharmaceutical University.
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is responsible for nearly half of all end-stage kidney disease and kidney failure is a major driver of mortality among patients with diabetes. To date, few safe and effective drugs are available to reverse the decline of kidney function. Kidney tubules producing energy by fatty acid metabolism are pivotal in development and deterioration of DKD. Peroxisome proliferator-activated receptors (PPARs), comprising PPARα, PPARδ and PPARγ play a senior role in the pathogenesis of DKD for their functions in glycemic control and lipid metabolism; whereas systemic activation of PPARγ causes serious side-effects in clinical settings. Compound H11 was a potent PPARα and PPARδ (PPARα/δ) dual agonist with potent and well-balanced PPARα/δ agonistic activity and a high selectivity over PPARγ. In this study, the potential therapeutic effects of compound H11 were determined in a db/db mouse model of diabetes. Expressions of PPARα and PPARδ in nuclei of tubules were markedly reduced in diabetes. Transcriptional changes of tubular cells showed that H11 was an effective PPARα/δ dual agonist taking effects both in vivo and in vitro. Systemic administration of H11 showed glucose tolerance and lipid metabolic benefits in db/db mice. Moreover, H11 treatment exerted protective effects on diabetic kidney injury. In addition to fatty acid metabolism, H11 also regulated diabetes-induced metabolic alternations of branch chain amino acid degradation and glycolysis. The present study demonstrated a crucial role of H11 in regulation of energy homeostasis and metabolism in glucose-treated tubular cells. Overall, compound H11 holds therapeutic promise for DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Kidney Disease, The Second Affiliated Hospital of Nanjing Medical University, China.
- Center for Kidney Disease, The Second Affiliated Hospital of Nanjing Medical University, China. Electronic address: jianglei@njmu.edu.cn.
- Center for Kidney Disease, The Second Affiliated Hospital of Nanjing Medical University, China. Electronic address: jwyang@njmu.edu.cn.
- Center for Kidney Disease, The Second Affiliated Hospital of Nanjing Medical University, China. Electronic address: zhouyang@njmu.edu.cn.
Förderung
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- China Pharmaceutical University
Zitieren
APA
Ke, Q., Xiao, Y., Liu, D., Shi, C., Shen, R., Qin, S., Jiang, L., Yang, J., & Zhou, Y. (2024). PPARα/δ dual agonist H11 alleviates diabetic kidney injury by improving the metabolic disorders of tubular epithelial cells. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116076
Vancouver
Ke Q, Xiao Y, Liu D, Shi C, Shen R, Qin S, et al. PPARα/δ dual agonist H11 alleviates diabetic kidney injury by improving the metabolic disorders of tubular epithelial cells. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116076
BibTeX
@article{Ke2024,
author = {Ke, Qingqing and Xiao, Yu and Liu, Dandan and Shi, Caifeng and Shen, Rui and Qin, Songyan and Jiang, Lei and Yang, Junwei and Zhou, Yang},
title = {PPARα/δ dual agonist H11 alleviates diabetic kidney injury by improving the metabolic disorders of tubular epithelial cells},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116076}
}
EUVIMED